Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $157.5 million.

  • Ascendis Pharma A's Receivables - Net rose 33333.25% to $157.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.5 million, marking a year-over-year increase of 33333.25%. This contributed to the annual value of $180.0 million for FY2024, which is 36626.75% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Receivables - Net of $157.5 million as of Q3 2025, which was up 33333.25% from $125.0 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Receivables - Net ranged from a high of $177.7 million in Q4 2024 and a low of $72374.2 during Q1 2021
  • In the last 5 years, Ascendis Pharma A's Receivables - Net had a median value of $22.0 million in 2023 and averaged $42.4 million.
  • In the last 5 years, Ascendis Pharma A's Receivables - Net tumbled by 8023.09% in 2021 and then soared by 890671.85% in 2022.
  • Ascendis Pharma A's Receivables - Net (Quarter) stood at $2.5 million in 2021, then soared by 382.81% to $12.2 million in 2022, then surged by 217.65% to $38.6 million in 2023, then skyrocketed by 360.35% to $177.7 million in 2024, then fell by 11.35% to $157.5 million in 2025.
  • Its Receivables - Net was $157.5 million in Q3 2025, compared to $125.0 million in Q2 2025 and $70.1 million in Q1 2025.